INTRODUCTION
============

Cancer is the second leading cause of death worldwide after cardiovascular diseases. Among all cancers, colorectal cancer (CRC) is the third most common malignancy in men and the second most common malignancy in women worldwide. In 2015, 1.7 million incidences of CRC occurred globally, and the resultant 832,000 patients died.[@b1-jcp-22-241],[@b2-jcp-22-241] Due to the improved survival rates resulting from early diagnosis and improved treatment, the survival of cancer patients has increased, and this trend will continue.[@b3-jcp-22-241] Therefore, late outcomes of CRC survivors resulting in complications, such as increased risk of second primary malignancies (SPMs), has become an important issue.[@b4-jcp-22-241] Prostate cancer, the most common cancer diagnosis, is the third leading cause of death in men, with more than 1.6 million new cases in 2015.[@b1-jcp-22-241],[@b5-jcp-22-241] Recently, increasing evidence supports the hypothesis that metabolic syndrome is involved in the development and progression of certain types of malignancies;[@b6-jcp-22-241] thus, it can be inferred that CRC may share common risk factors for several metabolic syndrome-related cancers, including prostate cancer. The prevalence of CRC and prostate cancer in Asian countries has increased, and this may be due to the adoption of a westernized lifestyle, and subsequently increasing incidence of metabolic syndrome.[@b7-jcp-22-241]

Although some studies have reported the occurrence of secondary primary prostate cancer (SPPC) after CRC, the results are inconsistent.[@b2-jcp-22-241] Furthermore, some clinicians have demonstrated a high incidence of SPPC in CRC patients, but others have not confirmed any such results.[@b8-jcp-22-241]--[@b11-jcp-22-241] Thus, knowledge of the incidence of SPPC in CRC survivors is necessary for an effective surveillance program as well as to direct attention to organs vulnerable to secondary malignancies.[@b12-jcp-22-241] Using this background, we analyzed the cohort data from the National Health Insurance System (NHIS) in Korea, to investigate the association of the development of SPPC among patients with prior primary CRC.

MATERIALS AND METHODS
=====================

1. Data source
--------------

We analyzed data from the NHIS database, registration for which is mandatory for all Koreans. NHIS is responsible for the national health checkup programs, which include a general health examination for all insured employees or self-employed persons aged \> 40 years. NHIS recommends a semi-compulsive health checkup to be undertaken at least biennially. The NHIS database includes an eligibility database (age, sex, socioeconomic variables, type of eligibility, and income level), a medical treatment database (based on the medical records by International Statistical Classification of Diseases and Related Health Problems (ICD) codes that were claimed by medical service providers for their medical expense claims), a health examination database (results of general health examinations and questionnaires on lifestyle and behavior), and a medical care institution database (types of medical care institutions, location, equipment, and number of physicians).[@b13-jcp-22-241]--[@b15-jcp-22-241] Since the study involved routinely collected data, obtaining informed consent was not required. All procedures involving human participants were performed in accordance with the ethical standards of the institutional and national research committees, and 1964 Helsinki declaration including its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (X-1708-417-905).

2. Study population
-------------------

The incidences of SPPC among men diagnosed with CRC (ICD-10 codes C18, C19, and C20) were compared with those of randomly selected controls. The control group, from the general population, was matched to CRC patients, according to age at a 1 : 5 ratio. The primary outcome was the diagnosis of SPPC (ICD-10 codes C61) after a diagnosis of CRC. To exclude the possibility of synchronous or metastatic CRC, patients with a diagnosis of a prostate cancer within a latency period of 1 year after CRC diagnosis were excluded. This cohort was followed-up from January 1, 2007 until December 31, 2015, to identify the development SPPC.

In addition, people previously diagnosed with cancer other than CRC were excluded. Information about the date of diagnosis of previous CRC, latency period, yearly income, and comorbidities (diabetes mellitus, hypertension, and dyslipidemia) was extracted from the database. Finally we enrolled a total of 85,455 CRC patients. We performed additional subgroup analysis for people (n = who had health checkups within 1 year before CRC diagnosis). In this analysis, body mass index (BMI), alcohol consumption, exercise, and smoking were included as confounding factors in addition to age, sex, income and residence, diabetes mellitus, hypertension, and dyslipidemia. This is summarized in [Figure 1](#f1-jcp-22-241){ref-type="fig"}.

3. Definitions
--------------

Diabetes mellitus was defined as fasting blood glucose ≥ 126 mg/dL, 2-hour plasma glucose ≥ 200 mg/dL during an oral glucose tolerance test, or use of antidiabetic medications.[@b16-jcp-22-241] Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or use of antihypertensive drugs.[@b17-jcp-22-241] Dyslipidemia was defined as any one of the following: total cholesterol ≥ 240 mg/dL, triglyceride ≥ 150 mg/dL, low-density lipoprotein cholesterol ≥140 mg/dL, high-density lipoprotein cholesterol \< 40 mg/dL, or use of lipid-l owering drugs.[@b18-jcp-22-241] Income \< 20% of the mean value of the total population was classified as low household income. Residential areas were divided into two groups (urban or rural), with urban areas defined as metropolitan cities with a population of \> 1 million. The smoking group included ex-smokers and current smokers, and was defined as patients who smoked at least five pack years of cigarettes in their whole lives. Alcohol consumption status was categorized as nondrinkers and alcohol drinkers, and was defined as those who drank alcohol at least once a week.

Regular exercise was defined as physical activity more than three times a week for more than 20 minutes. BMI was calculated by dividing body weight by the square of the persons height, with overweight defined as BMI \>23 kg/m^2^ and obesity as BMI \>

25 kg/m^2^. Blood samples were collected after a fasting period of at least 8 hours.

4. Statistical analysis
-----------------------

Propensity score matching was used to generate the control group. Continuous variables with a normal distribution were analyzed using the Student's *t*-test. HRs and 95% CIs were calculated via statistical analysis using the Cox regression models after controlling for age, sex, BMI, smoking, alcohol consumption, exercise, diabetes mellitus, hypertension, dyslipidemia, and income. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 3.2.3 (The R Foundation for Statistical Computing, Vienna, Austria; <http://www.Rproject.org>). A two-sided *P*-value of \< 0.05 was considered to be statistically significant.

RESULTS
=======

1. Demographics
---------------

We analyzed 430,494 men without CRC and 110,289 healthy males who were registered in the NHIS database between 2007 and 2012. After excluding individuals who were diagnosed with a previous malignancy within 1 year of CRC, 85,455 male CRC patients and age-matched 430,494 control subjects were finally included in the analysis ([Fig. 1](#f1-jcp-22-241){ref-type="fig"}). The basic demographics of this cohort are presented in [Table 1](#t1-jcp-22-241){ref-type="table"}. In the CRC group, the proportions of diabetes mellitus, hypertension, and dyslipidemia (all *P* \< 0.0001) were significantly higher than those in the control group. Subjects whose yearly income was in the bottom 20% among the total population, were significantly less common in the CRC group than general population. The proportion of residents in urban areas was significantly higher in the CRC group than general population.

2. Risk for development of secondary primary prostate cancers in colorectal cancer patients
-------------------------------------------------------------------------------------------

During the median follow-up period of 5.78 years, 2,005 patients (2.30%) developed SPPC in the CRC group, while 4,415 subjects with prostate cancer (1.03%) were confirmed in the control group. The Cox regression model was used to predict the potential risk factors for SPPC. The incidence rate (IR) of SPPC among CRC patients was 4.06/1,000 person-years and HR was 2.30 (95% CI, 2.18--2.43); HR was higher in subjects aged \< 55 years than those aged ≥ 55 years (HR, 8.95; 95% CI, 7.33--10.92) ([Table 2](#t2-jcp-22-241){ref-type="table"}).

The cumulative incidence of prostate cancer in each group over time is presented in [Figure 2](#f2-jcp-22-241){ref-type="fig"}. The cumulative incidence of SPPC among CRC patients was 0.2% at 5 years after diagnosis. The cumulative incidence of SPPC in CRC patients was continuously higher than that in the general population, representing 0.05% at 5 years after the diagnosis of CRC (IR 4.06 vs. 1.76/1,000 person-years, respectively).

3. Subgroup analysis
--------------------

Among CRC patients who underwent health checkups within 1 year before CRC diagnosis, 21,823 patients were matched to 110,289 subjects in the control group using the health checkup data according to age at a 1 : 5 ratio. The basic demographics are presented in [Table 3](#t3-jcp-22-241){ref-type="table"}. Individuals with diabetes mellitus, hypertension, and dyslipidemia (all *P* \< 0.0001) were significantly more common in the CRC group than in the control group. Current smoking, alcohol consumption, and BMI were not significantly different between both groups. We identified IR and HR of prostate cancer after adjusting for confounders. Multivariate analysis demonstrated that CRC patients remained significantly independent predictors of SPPC development (IR 4.56/1,000 person-years, HR 2.90; 95% CI, 2.58--3.27) ([Table 2](#t2-jcp-22-241){ref-type="table"}). In this subgroup analysis, younger CRC patients, particularly those diagnosed at \< 55 years of age were significantly associated with a higher risk of SPPC (HR, 20.74; 95% CI, 11.81--36.41). [Table 4](#t4-jcp-22-241){ref-type="table"} demonstrates that the association between development of SPPC and CRC is higher in younger patients who are diagnosed with CRC.

DISCUSSION
==========

In the present nationwide population-based cohort study, we demonstrated that the incidence of SPPC is higher in CRC patients than in individuals without previous malignancies. This risk was particularly higher in men aged \< 55 years than in others.

There are several reports on SPMs among CRC survivors; however, only a few studies exist on the development of SPPC in CRC patients. Evans et al.[@b2-jcp-22-241] demonstrated that CRC patients aged \<60 years are at risk of SPMs in other sites. Phipps et al.[@b19-jcp-22-241] reported a slightly increased risk of secondary non-CRC using the Surveillance, Epidemiology, and End Results (SEER) registries with a standardized incidence ratio (SIR) of 1.24. Ahmed et al.[@b20-jcp-22-241] studied the excess risk of subsequent primary cancers among CRC survivors. They used SEER and reported the significantly elevated SIR of 26.48 in only black males. Moot et al.[@b21-jcp-22-241] investigated the relationship between CRC and SPPC. They showed that men who develop CRC are at an increased risk of SPPC (SIR at follow-up period: \< 1 year, 1.7; 1--5 years, 1.3; 5--10 years, 1.4), with the highest risk in men aged \< 65 years. Furthermore, Lee et al.[@b4-jcp-22-241] reported that the risk of SPPC was 1.2 times higher in CRC patients than general population.

The mechanism of the increased risk for SPPC in patients has not yet been proved. Several etiologies, including existing background, lifestyle, comorbidities, and environmental components are related to the development of SPPC. For example, hereditary nonpolyposis CRC patients tend to develop other extracolonic malignancies more than the general population.[@b22-jcp-22-241] In addition, there may be unknown shared etiological factors that are involved in the link between the CRC and SPPC.[@b23-jcp-22-241]--[@b25-jcp-22-241] SPPC development may also be related to daily lifestyle factors, such as saturated fat intake, which has been implicated in both CRC and prostate cancer.[@b26-jcp-22-241]--[@b28-jcp-22-241] In addition, the treatment of CRC can cause the development of SPMs. For example, chemotherapy and radiation are related to SPMs; however, the exact mechanism is not yet proved.[@b29-jcp-22-241],[@b30-jcp-22-241]

Another explanation is that the increased incidence of SPPC may result from a screening detection bias, which has been suggested.[@b31-jcp-22-241] Men previously diagnosed with CRC can be followed-up more closely than those without any previous malignancies, including frequent digital rectal examinations. Given that CRC survivors were twice as risky as the general population without previous malignancies, and that this risk was higher in young patients, the importance of screening or surveillance is raised. However, there is considerable doubt whether physicians will be able to identify a curable lesion localized to the prostate gland. Although it is uncertain whether blood tests using prostate-specific antigens are effective for screening CRC survivors,[@b32-jcp-22-241]--[@b34-jcp-22-241] our results suggest that further studies are required to determine the link between CRC and SPPC, as well as strategies for prevention.

The present study had several limitations. First, we did not classify CRC patients according to treatment based on the stage of the disease, making it impossible to assess the correlation between disease severity, treatment modality, and incidence of SPPC. Second, the development of prostate cancer is time demanding; therefore, a longer follow-up period would have yielded a remarkable result. Finally, in addition to the BMI, smoking, alcohol consumption, exercise, hypertension, and diabetes mellitus, there are many other related factors between CRC and SPPC, such as lifestyle, eating habits, family history etc. In this point of view, bias exists and it is worth mentioning as a limitation. There are some advantages of this study. This is a population-based nationwide study using the NHIS database. This database records the claims information of approximately 97% of all Koreans. Therefore, it represents almost the entire Korean population. Because all patients registered for cancer require a confirmation by biopsy, the record of the diagnosis of cancer is reliable. In addition, we analyzed health checkup data for the first time. Using the health checkup claim data, we adjusted for potential confounding factors (BMI, diabetes mellitus, dyslipidemia, smoking, and alcohol consumption) that could affect the progression to prostate cancer.

In conclusion, this nationwide population-based study suggests that CRC patients are at an increased risk of SPPC, especially young patients aged \<55 years. Early detection of prostate cancer, which has an elevated likelihood of occurring in CRC patients, is important. Therefore, as next steps, we suggest implementation of proper screening techniques for prostate cancer and investigating the possible shared etiologies and mechanisms of carcinogenesis.
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###### 

Baseline characteristics of the study population

  Variable                                                         Healthy population   CRC patient      *P*-value
  ---------------------------------------------------------------- -------------------- ---------------- -----------
  Sex (male)                                                       430,494 (100)        85,455 (100)     
  Age                                                                                                    
   \< 55 yr                                                        105,383 (24.48)      20,953 (24.52)   \< 0.0001
   ≥ 55 yr                                                         325,111 (75.52)      64,502 (75.48)   \< 0.0001
  Low household income[a](#tfn2-jcp-22-241){ref-type="table-fn"}   101,518 (23.58)      19,066 (22.31)   \< 0.0001
  Urban residents[b](#tfn3-jcp-22-241){ref-type="table-fn"}        194,175 (45.11)      39,676 (46.43)   \< 0.0001
  Diabetes mellitus                                                59,992 (13.94)       16,692 (19.53)   \< 0.0001
  Hypertension                                                     147,766 (34.32)      34,639 (40.53)   \< 0.0001
  Dyslipidemia                                                     63,824 (14.83)       13,548 (15.85)   \< 0.0001
  Development of prostate cancer                                   4,415 (1.03)         2,005 (2.35)     \< 0.0001

Values are presented as number (%). CRC, colorectal cancer.

The low household income refers to those who are in the bottom 20% of the total population.

Urban residents refer to people living in metropolitan areas with a population of over 1 million.

###### 

IR and HR for development of secondary prostate cancer after adjustment for confounding factors

  Population                     Development of PC   Duration[a](#tfn5-jcp-22-241){ref-type="table-fn"}   IR[b](#tfn6-jcp-22-241){ref-type="table-fn"}   HR (95% CI)                                                                                                                    
  ------------------------------ ------------------- ---------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------
  Total population                                                                                                                                                                                                                                                                      
   Control group (n = 430,494)   4,415               2,506,315                                            1.76                                           1 (ref)                                                       1 (ref)                                                          1 (ref)
   CRC patients (n = 85,455)     2,005               494,191                                              4.06                                           2.30[c](#tfn7-jcp-22-241){ref-type="table-fn"} (2.18--2.43)   8.95[c](#tfn7-jcp-22-241){ref-type="table-fn"} (7.33--10.92)     2.07[c](#tfn7-jcp-22-241){ref-type="table-fn"} (1.96--2.19)
   *P*-value                                                                                                                                             \< 0.0001                                                     \< 0.0001                                                        \< 0.0001
  Subgroup analysis                                                                                                                                                                                                                                                                     
   Control group (n = 110,289)   4,415               490,643                                              1.58                                           1 (ref)                                                       1 (ref)                                                          1 (ref)
   CRC patients (n = 21,823)     441                 96,692                                               4.56                                           2.90[d](#tfn8-jcp-22-241){ref-type="table-fn"} (2.58--3.27)   20.74[d](#tfn8-jcp-22-241){ref-type="table-fn"} (11.81--36.41)   2.55[d](#tfn8-jcp-22-241){ref-type="table-fn"} (2.25--2.88)
   *P*-value                                                                                                                                             \< 0.0001                                                     \< 0.0001                                                        \< 0.0001

IR, incidence rate; PC, prostate cancer; ref, reference value; CRC, colorectal cancer.

The unit of duration is person-year.

IR means the number of prostate cancer patients per 1,000 people-years.

Adjusted by age.

Adjusted for age, sex, body mass index, drink, exercise, income, diabetes mellitus, hypertension, dyslipidemia.

###### 

General characteristics of the study population (health checkup)

  Variable                                                            Healthy population (n=110,289)   CRC patient (n=21,823)   *P*-value
  ------------------------------------------------------------------- -------------------------------- ------------------------ -----------
  Sex (male)                                                          110,289 (100)                    21,823 (100)             
  Age                                                                                                                           0.1494
   \< 55 yr                                                           27,046 (24.52)                   5,452 (24.98)            
   ≥ 55 yr                                                            83,243 (75.48)                   16,371 (75.02)           
  BMI                                                                                                                           0.2922
   \< 18.5 kg/m^2^                                                    6,375 (5.78)                     1,337 (6.13)             
   18.5--23 kg/m^2^                                                   46,074 (41.78)                   9,110 (41.74)            
   23--25 kg/m^2^                                                     23,687 (21.48)                   4,656 (21.34)            
   25--30 kg/m^2^                                                     29,064 (26.35)                   5,689 (26.07)            
   25--30 kg/m^2^                                                     5,089 (4.61)                     1,031 (4.72)             
  Ever smoker (yes)[a](#tfn10-jcp-22-241){ref-type="table-fn"}        39,979 (36.25)                   7,989 (36.61)            0.3138
  Drinking alcohol \>1/wk (yes)                                       46,298 (41.98)                   9,277 (42.51)            0.1463
  Regular exercise (yes)[b](#tfn11-jcp-22-241){ref-type="table-fn"}   22,578 (20.47)                   4,379 (20.07)            0.1742
  Diabetes mellitus                                                   23,353 (21.17)                   5,669 (25.98)            \< 0.0001
  Hypertension                                                        50,395 (45.69)                   11,042 (50.60)           \< 0.0001
  Dyslipidemia                                                        28,464 (25.81)                   5,849 (26.80)            0.0022
  Development of prostate cancer                                      773 (0.7)                        441 (2.02)               \< 0.0001
  Height (cm)                                                         161.4 ± 9.4                      161.5 ± 9.4              0.1185
  Weight (kg)                                                         61.5 ± 11.6                      61.5 ± 11.8              0.8463
  BMI (kg/m^2^)                                                       23.5 ± 3.6                       23.5 ± 3.6               0.3341
  SBP (mmHg)                                                          122 ± 15.9                       122.1 ± 15.9             0.8874
  DBP (mmHg)                                                          75.9 ± 10.3                      75.9 ± 10.3              0.9944
  TC (mg/dL)                                                          191.2 ± 38.4                     191 ± 38.7               0.5146

Values are presented as number (%) or mean ± SD. The subjects of this analysis are those who have health check-up data before the diagnosis of colorectal cancer. CRC, colorectal cancer; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol.

Ever smoker is a person who has smoked at least five packs of cigarettes in their lives with the sum of ex-smoker and current smoker.

Regular exercise refers to a person exercising at least three times a week.

###### 

Incidence rate of SPPC by age according to CRC

  Age (yr)   Group           Number    Development of SPPC   Duration[a](#tfn13-jcp-22-241){ref-type="table-fn"}   IR[b](#tfn14-jcp-22-241){ref-type="table-fn"}   HR (95% CI)
  ---------- --------------- --------- --------------------- ----------------------------------------------------- ----------------------------------------------- ----------------------
  \< 60s     Control group   163,927   431                   953,860.87                                            0.45185                                         1 (ref)
             CRC patients    32,603    502                   188,512.34                                            2.66296                                         5.922 (5.207--6.736)
  60s        Control group   138,339   1720                  815,065.91                                            2.11026                                         2.467 (2.15--2.83)
             CRC patients    27,404    764                   160,157.54                                            4.7703                                          5.581 (4.817--6.466)
  70s        Control group   103,808   1950                  598,340.56                                            3.25901                                         2.439 (2.029--2.933)
             CRC patients    20,586    642                   117,938.96                                            5.44349                                         4.081 (3.358--4.96)
  80s        Control group   24,420    314                   139,048.39                                            2.25821                                         1.044 (0.8--1.363)
             CRC patients    4,862     97                    27,583.04                                             3.51665                                         1.625 (1.188--2.223)

These results are obtained by health checkup data. SPPC, secondary primary prostate cancer; CRC, colorectal cancer; IR, incidence rate; ref, reference value.

The unit of duration is person-year.

IR means the number of prostate cancer patients per 1,000 people-years.
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